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Brucella ovis is a non-zoonotic Brucella species lacking specific vaccine. It presents a
narrow host range, a unique biology relative to other Brucella species, and important
distinct surface properties. To increase our knowledge on its peculiar surface and
virulence features, and seeking to develop a specific vaccine, multiple mutants for nine
relevant cell-envelope-related genes were investigated. Mutants lacking Omp10 plus
Omp19 could not be obtained, suggesting that at least one of these lipoproteins is
required for viability. A similar result was obtained for the double deletion of omp31
and omp25 that encode two major surface proteins. Conversely, the absence of major
Omp25c (proved essential for internalization in HeLa cells) together with Omp25 or
Omp31 was tolerated by the bacterium. Although showing important in vitro and
in vivo defects, the 1omp101omp311omp25c mutant was obtained, demonstrating
that B. ovis PA survives to the simultaneous absence of Omp10 and four out
seven proteins of the Omp25/Omp31 family (i.e., Omp31, Omp25c, Omp25b, and
Omp31b, the two latter naturally absent in B. ovis). Three multiple mutants were
selected for a detailed analysis of virulence in the mouse model. The 1omp311cgs
and 1omp101omp311omp25c mutants were highly attenuated when inoculated at
106 colony forming units/mouse but they established a persistent infection when the
infection dose was increased 100-fold. The 1omp101ugpB1omp31 mutant showed
a similar behavior until week 3 post-infection but was then totally cleared from spleen.
Accordingly, it was retained as vaccine candidate for mice protection assays. When
compared to classical B. melitensis Rev1 heterologous vaccine, the triple mutant
induced limited splenomegaly, a significantly higher antibody response against whole
B. ovis PA cells, an equivalent memory cellular response and, according to spleen
colonization measurements, better protection against a challenge with virulent B. ovis
PA. Therefore, it would be a good candidate to be evaluated in the natural host as
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a specific vaccine against B. ovis that would avoid the drawbacks of B. melitensis
Rev1. In addition, the lack in this attenuated strain of Omp31, recognized as a highly
immunogenic protein during B. ovis infection, would favor the differentiation between
infected and vaccinated animals using Omp31 as diagnostic target.
Keywords: Brucella ovis, outer membrane, virulence, recombinant vaccine, Omp31, Omp25/Omp31 family, cyclic
glucans, lipoprotein
INTRODUCTION
Brucella ovis is a Gram-negative bacterial species belonging
to the genus Brucella. It is a non-zoonotic species mainly
provoking epididymitis and other genital lesions in rams,
although it has also been associated with increased perinatal
mortality in lambs and placentitis, abortions, and infertility
in ewes (OIE, 2017b). It causes significant economic losses
worldwide and lacks commercially available specific vaccine.
B. ovis lipopolysaccharide (LPS) is devoid of O-polysaccharide
(O-PS) chains and is defined as rough (R) LPS (R-LPS). B. ovis
and B. canis are the sole species of the Brucella genus constituted
exclusively by R strains that are virulent for their natural
hosts. This characteristic differentiates them from smooth (S)
brucellae that require O-PS for full virulence (e.g., B. melitensis,
B. abortus, or B. suis). B. melitensis Rev1, currently used for
vaccination against ovine and caprine brucellosis caused by
B. melitensis, is considered the best available vaccine against
B. ovis (OIE, 2017a). However, this vaccine is banned in
countries or regions where infection by B. melitensis is eradicated
because, among other drawbacks, it induces antibodies that
interfere with the serological diagnosis of infections caused
by S brucellae. Therefore, the development of a specific
vaccine for the prophylaxis of B. ovis infection is a matter of
interest. Considering that the best available vaccines against
brucellosis caused by S Brucella strains are homologous S
attenuated strains (Nicoletti, 2010), the search for a B. ovis
attenuated vaccine strain seems an interesting approach. The
first step to achieve this goal is the identification of virulence
factors that can be removed from B. ovis, to minimize its
deleterious effects on the host, but without compromising its
immunogenicity.
Comparatively to its S counterparts, little is known about
the virulence of B. ovis, although a species-specific ABC
transporter (Silva et al., 2011, 2013) and some classical
virulence factors described in S species have been identified
as necessary for its virulence (Martín-Martín et al., 2012; Sá
et al., 2012; Macedo et al., 2015). O-PS chains mask other outer
membrane (OM) components in S strains (Cloeckaert et al.,
2002), hindering their interaction with host cells, antibodies,
and other elements of the immune system. According to
the surface exposure of OM molecules other than LPS in
R B. ovis, a more important role in the interaction with
host cells and virulence than in S strains would be expected.
However, several OM proteins (OMPs) and OM-related genes
necessary for full virulence in S strains seem not required in
B. ovis experimental infection models (Martín-Martín et al.,
2012; Sidhu-Muñoz et al., 2016). This observation reveals
differences among the brucellae regarding the role of the
OM molecules in host–pathogen interactions, differences that
might be associated with their heterogeneity regarding OM-
related properties (Martín-Martín et al., 2011; Vizcaíno and
Cloeckaert, 2012), host-preference, and pathogenicity. Although
the Brucella species share a high level of DNA homology,
an increased number of pseudogenes and insertion sequences
has been detected in B. ovis, when compared to zoonotic S
Brucella (Tsolis et al., 2009). This feature led to hypothesize
that its narrow host-range and tissue tropism (almost exclusively
restricted to ovine male genital tract) is in part consequence
of genome degradation (Tsolis et al., 2009). However, despite
this genome degradation, that among others affects O-PS
biosynthetic genes and several OMPs (Tsolis et al., 2009),
B. ovis causes a chronic infection in its natural host and
in laboratory animals (Caro-Hernández et al., 2007; Silva
et al., 2011; OIE, 2017b), which would also support a specific
pattern of interaction between the host and the bacterial
OM.
With the aim of increasing our knowledge about the
contribution of cell envelope components to OM-related
properties and virulence of B. ovis and as a tool to develop a
specific live attenuated vaccine, in this work we have constructed
and characterized a panel of B. ovis multiple mutants in genes
related to the cell envelope that either code for major OMPs
or either are individually required in S Brucella strains, but
not in B. ovis, for virulence (Caro-Hernández et al., 2007;
Martín-Martín et al., 2012; Sidhu-Muñoz et al., 2016). Genes
targeted in multiple mutations were: (i) omp31, omp25, and
omp25c that code for major OMPs in B. ovis (Cloeckaert
et al., 2002; Martín-Martín et al., 2009); (ii) omp10 and omp19
that encode two minor OM lipoproteins (Tibor et al., 1999)
required in B. abortus 544 for full virulence (Tibor et al.,
2002); (iii) bepC that encodes a TolC-homolog protein necessary
in B. suis 1330 for full virulence (Posadas et al., 2007); (iv)
bacA that encodes an integral inner membrane protein involved
in lipid A acylation, cell-envelope properties, and virulence
in B. abortus 2308 (LeVier et al., 2000; Roop et al., 2002;
Ferguson et al., 2004; Parent et al., 2007); and (v) ugpB that
encodes SP41, a surface protein involved in invasion of B. suis
1330 to HeLa cells (Castañeda-Roldán et al., 2006). Beside
these genes that are not individually required for virulence in
B. ovis PA, multiple mutations also included cgs, involved in
the synthesis of periplasmic cyclic β-1,2-glucans (CβGs) (Iñón
de Iannino et al., 1998; Haag et al., 2010) and necessary for
full virulence in B. abortus 2308 (Briones et al., 2001). The
1cgs mutant of B. ovis PA was also highly attenuated when
it was intraperitoneally inoculated at a dose of 106 colony
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forming units (CFU)/mouse (Martín-Martín et al., 2012), but
when the dose usually employed for protection experiments
(108 CFU/mouse) (Sancho et al., 2014; Soler-Lloréns et al., 2014;
Silva et al., 2015b) was used, the bacterial counts in spleen
increased to levels that were close to those of the parental
strain (unpublished results). Several combinations of deleted
genes were tempted in the panel of multiple mutants, although,
keeping in mind the development of an attenuated vaccine, the
inclusion of 1cgs and 1omp31 mutations was prioritized for
two reasons: (i) to study how the addition of new mutations
could increase the attenuation of the 1cgs single mutant to
appropriate levels for an attenuated vaccine, and (ii) Omp31 is
an abundant OMP in the OM of B. ovis PA (Martín-Martín
et al., 2009), it is the most immunogenic OMP in the course
of B. ovis infection (Kittelberger et al., 1998) and its interest
for a serological diagnosis favoring the differentiation between
infected and vaccinated animals (DIVA diagnosis) has also been
evidenced (Vizcaíno et al., 2001b).
MATERIALS AND METHODS
Bacterial Strains, Culture Conditions,
and Plasmids
Brucella ovis PA and B. melitensis Rev1 were obtained from
BCCN (Brucella Culture Collection Nouzilly, maintained at
the Institut National de la Recherche Agronomique, Nouzilly,
France), and the other B. ovis strains are listed in Table 1.
Recombinant plasmids used for mutagenesis of cgs (BOV_RS00
535), bacA (BOV_RS01960), omp10 (BOV_RS10700),
omp19 (BOV_RS09115), bepC (BOV_RS04655), and ugpB
(BOV_RS13470), and the corresponding single mutants
derived from parental B. ovis PA have previously been
described (Martín-Martín et al., 2012; Sidhu-Muñoz et al.,
2016). B. ovis 1omp31 (BOV_RS12205) and 1omp25
(BOV_RS3460) single nonpolar mutants (Table 1) were
obtained from parental B. ovis PA as described below.
Multiple mutants (Table 1) were constructed from initial
single mutants where one or two of the mentioned genes
were additionally deleted. The 1omp31-k and 1omp25c-k
mutant strains (omp31 or omp25c replaced by a kanamycin
resistance cassette) and the same mutants complemented
with the corresponding omp31 or omp25c (BOV_RS00575)
wild type genes (1omp31-k com and 1omp25c-k com
strains) were previously obtained (Caro-Hernández et al.,
2007).
Brucella ovis strains and the B. melitensis Rev1 attenuated
vaccine were cultured in tryptic soy agar or tryptic soy broth
(Pronadisa-Laboratorios Conda, Torrejón de Ardoz, Spain)
both supplemented with 0.3% yeast extract (Pronadisa-
Laboratorios Conda, Torrejón de Ardoz, Spain) and 5%
horse serum (Gibco-Life Technologies, Grand Island, NY,
United States) (TSA-YE-HS and TSB-YE-HS, respectively).
Incubations were performed at 37◦C in a 5% CO2 atmosphere
and, in the case of TSB-YE-HS liquid medium, under
agitation at 120 rpm. When required, streptomycin (Strep;
50 µg/ml) (Sigma-Aldrich, St. Louis, MO, United States)
was added to the culture medium of B. melitensis Rev1
(Strep-resistant strain). Similarly, when necessary for the
selection of the recombinant B. ovis strains, kanamycin
(50 µg/ml) or 5% sucrose (Sigma-Aldrich, St. Louis, MO,
United States) was added. Assays with the B. ovis strains,
including 1omp31-k, 1omp25c-k, 1omp31-k com, and
1omp25c-k com strains, were performed in the absence of
antibiotics.
Plasmid pGEM-T Easy (Promega, Madison, WI,
United States) was used to clone PCR-amplified fragments
and pCVD-KanD (Martín-Martín et al., 2012) was the suicide
plasmid employed to insert the mutant genes into parental
B. ovis PA. They were propagated in Escherichia coli JM109 or
CC118 (λpir), respectively, that were incubated at 37◦C in Luria
Bertani medium supplemented, when required, with ampicillin
or kanamycin (50 µg/ml). Their derived recombinant plasmids
constructed during this work are mentioned below.
DNA Primers and Mutagenesis
DNA primers (IDT, Leuven, Belgium) used for the
construction and verification of the B. ovis 1omp31,
1omp25, and 1omp25c single and multiple nonpolar
mutants are listed in Table 2. The additional primers
used to check the multiple mutants were previously
described (Martín-Martín et al., 2012; Sidhu-Muñoz et al.,
2016).
For the construction of the recombinant plasmids used
in the mutagenesis process, inactivation of omp31, omp25,
and omp25c was performed by in-frame deletion with
overlapping PCR (Martín-Martín et al., 2012). Briefly, the
5′- and 3′-ends of each target gene, together with about
300–700 pb upstream or downstream, respectively, were
separately amplified by PCR with two pairs of primers
(31MUT-F + 31OVL-R and 31OVL-F+ 31MUT R for omp31,
25MUTZ-F + 25OVL-R and 25OVL-F + 25MUTZ-R for
omp25, 25cdMUT-F+ 25cOVL-R and 25cOVL-F+ 25cMUT-R)
(Table 2). The two amplified fragments were fused, through
the overlapping sequences located in the internal primers
(primers OVL-F and OVL-R) (Table 2), in a PCR reaction
with the two external primers of each fragment (31MUT-
F + 31MUT-R for omp31, 25MUTZ-F + 25MUTZ-R for
omp25, and 25cdMUT-F + 25cMUT-R for omp25c). The
resulting mutant genes were cloned in pGEM-T Easy,
verified by DNA sequencing, and subsequently cloned in
pCVD-KanD to give pPS31OVL02, pNV25OVL02, and
pNV25cOVL02, respectively. Plasmids were introduced
in B. ovis PA by electroporation and the selection of
bacteria with the corresponding plasmid integrated in
the chromosome (intermediate strains), through a single
homologous recombination event, was performed on TSA-
YE-HS plates with kanamycin. The selected intermediate
strains were plated onto TSA-YE-HS supplemented with 5%
sucrose to give either the desired mutant strain (wild-type
gene replaced by the inactivated gene) or a strain reverting
to the parental genotype (Rv). They were differentiated by
PCR amplification with the two primers external to each side
of the deleted gene (amplified fragment with higher size in
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TABLE 1 | Most relevant bacterial strains used in this work, growth characteristics, and preliminary evaluation of virulence.
Log CFU/spleen at week (W) p.i.c
Deleted gene/s and strain Log CFU/ml (dose 106 CFU) (dose 108 CFU)
Brucella ovis strainsa abbreviation in the text OD600 = 0.2b W3 W7 W3 W7
B. ovis PA (BCCN 76-250) Parental strain, PA 9.09 ± 0.04 6.90 5.85 7.62 6.31
Single mutants
B. ovis-pPS31OVL02M 1omp31 8.80 ± 0.10∗ 5.44 5.79 – –
B. ovis-pNV25OVL02M 1omp25 9.08 ± 0.07 6.87 4.92 – –
B. ovis-PNV25cA 1omp25c-k 8.93 ± 0.03∗ 7.20 5.61 – –
B. ovis-pNVcgs03M 1cgs 8.88 ± 0.08∗ 0.45 0.53 6.20 5.53
B. ovis-pNVbacA03M 1bacA 9.12 ± 0.07 6.48 5.64 – –
B. ovis-pNV1002M 1omp10 8.84 ± 0.04∗ 6.91 5.79 – –
B. ovis-pNV1902M 1omp19 8.92 ± 0.05∗ 6.51 5.90 – –
B. ovis-pNVBepC02M 1bepC 9.15 ± 0.08 6.17 5.28 – –
B. ovis-pNVSP4102M 1ugpB 9.10 ± 0.03 7.72 6.30 – –
Double mutants
B. ovis 1omp31-pNV1902M 1omp311omp19 8.78 ± 0.04∗ 5.25 5.92 – –
B. ovis 1omp31-pNVBepC02M 1omp311bepC 8.80 ± 0.04∗ 6.78 5.75 – –
B. ovis 1omp31-pNVSP4102M 1omp311ugpB 8.82 ± 0.06∗ 5.90 6.32 – –
B. ovis 1omp31-pNVcgs03M 1omp311cgs 8.49 ± 0.09∗ – – 5.16 4.95
B. ovis 1omp25-pNVcgs03M 1omp251cgs 8.56 ± 0.06∗ – – 5.52 5.15
B. ovis 1omp25-pNV25cOVL02M 1omp251omp25c 8.82 ± 0.06∗ 6.91 6.32 – –
B. ovis 1cgs-pNVSP4102M 1cgs1ugpB 8.89 ± 0.04∗ – – 5.24 4.80
B. ovis 1cgs-pNVBepC02M 1cgs1bepC 8.87 ± 0.07∗ – – 5.45 4.63
B. ovis 1omp10-pPS31OVL02M 1omp101omp31 8.89 ± 0.07∗ 6.72 6.66 – –
B. ovis 1omp10-pNVSP4102M 1omp101ugpB 8.91 ± 0.06∗ 7.29 5.66 – –
B. ovis 1omp10-pNVcgs03M 1omp101cgs 8.82 ± 0.09∗ – – 5.21 5.39
B. ovis 1omp19-pNVcgs03M 1omp191cgs 8.79 ± 0.03∗ – – 6.07 5.99
B. ovis 1omp19-pNVSP4102M 1omp191ugpB 8.88 ± 0.03∗ 6.57 5.36 – –
B. ovis 1bepC-pNVSP4102M 1bepC1ugpB 9.10 ± 0.05 7.37 5.63 – –
B. ovis 1bacA-pPS31OVL02M 1bacA1omp31 8.81 ± 0.02∗ 6.05 5.36 – –
Triple mutants
B. ovis 1omp101ugpB-pPS31OVL02M 1omp101ugpB1omp31 8.76 ± 0.18∗ 0.47 0.57 5.53 0.52
B. ovis 1omp101omp31-pNV25cOVL02M 1omp101omp311omp25c 8.49 ± 0.04∗ 2.57 3.26 5.30 5.70
B. ovis 1omp311omp10-pNV25cOVL02M 1omp311omp101omp25c 8.39 ± 0.03∗ 2.42 2.03 – –
B. ovis 1omp311cgs-pNV1002M 1omp311cgs1omp10 8.61 ± 0.07∗ – – 5.53 5.73
B. ovis 1omp311cgs-pNV1902M 1omp311cgs1omp19 8.71 ± 0.05∗ – – 5.07 4.61
B. ovis 1omp311bepC-pNVSP4102M 1omp311bepC1ugpB 8.86 ± 0.12∗ 7.65 6.00 – –
Other previous mutants used as controls
B. ovis PNV31A 1omp31-k 8.85 ± 0.03∗ – – – –
B. ovis PNV31A-com 1omp31-k com 8.89 ± 0.03∗ – – – –
B. ovis PNV25c-com 1omp25c-k com 8.99 ± 0.06 – – – –
aLog CFU/spleen 3 and 7 weeks after intraperitoneal infection with 1 × 106 or 1 × 108 CFU/mouse. One mouse was used per time point in this preliminary assay
of virulence. –, not determined. bThe B. ovis mutants derive from B. ovis PA, which was obtained from BCCN (Brucella Culture Collection Nouzilly, Institut National de
la Recherche Agronomique, Nouzilly, France). B. ovis 1cgs, 1bacA, 1omp10, 1omp19, 1bepC, and 1ugpB were previously described (Martín-Martín et al., 2012;
Sidhu-Muñoz et al., 2016). B. ovis PA 1omp25c-k and 1omp31-k were also previously obtained replacing omp25c and omp31, respectively, by a kanamycin resistance
cassette; they were complemented with wild-type omp25c and omp31, respectively, to give B. ovis 1omp25c-k com and B. ovis 1omp31-k com (Caro-Hernández et al.,
2007). The other B. ovis mutants were obtained in this work. cThe asterisk (∗) indicates statistically significant differences (P < 0.05), compared to the parental strain. Log
CFU/ml of bacterial suspensions adjusted to an OD600 value of 0.2. The results are expressed as the mean ± SD of three assays.
Rv strains than in mutant strains) and a second PCR with
an external primer and a primer annealing inside the deleted
fragment (primers 31-MAT, 25-MAT, and 25c-MAT) (Table 2).
The latter PCR reaction produces no amplification in mutant
strains.
For multiple gene mutagenesis, single mutants listed in
Table 1 were subjected to a second mutagenesis round with
a recombinant plasmid containing another inactivated gene.
A third round of mutagenesis was conducted on some selected
double mutants to inactivate a third gene. The selection of
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TABLE 2 | Primers used in this work for the construction and verification of
omp25, omp25c, and omp31 single and multiple mutantsa.
Primer name Nucleotide sequence 5′–3′b Target gene or
plasmidc
Construction of B. ovis PA mutants
25MUTZ-F CGACCTTATCCTCCTGAA omp25
25OVL-R GACGATTACGAGAGACTT omp25
25OVL-F AAGTCTCTCGTAATCGTC
AAGCTGGACACGCAGGAT
omp25
25MUTZ-R TTTGCGACGTTTTGCTGG omp25
25cdMUT-F TGCGTGGTTCAGATTTCG omp25c
25cOVL-R AGCCTTGAGCTTCATGAT omp25c
25cOVL-F ATCATGAAGCTCAAGGCT
GCTTACAAGTTCTGATAG
omp25c
25cMUT-R AGCCGTAACCAACCTGAC omp25c
31MUT-F AGAATAAAACACATGCCC omp31
31OVL-R GATGGACGCCAAAATTAC omp31
31OVL-F GTAATTTTGGCGTCCATC
GTCGGTCTGAACTACAAG
omp31
31MUT-R GCTGAATGCGGAGATGGT omp31
Additional primers for the verification of recombinant plasmids
and mutants
Universal-F GTTTTCCCAGTCACGAC pGEM-T Easy
Universal-R CAGGAAACAGCTATGAC pGEM-T Easy
25-Sec GGACCGCGCAAAACGTAATT omp25
25-MAT GCCGACGCCATCCAGGAA omp25
25c-MAT GCTGACGCCGTCATTGAA omp25c
31-MAT GCCGACGTGGTTGTTTCT omp31
aPrimers for the verification of proper deletion of other genes have been
previously described (Martín-Martín et al., 2012; Sidhu-Muñoz et al., 2016).
bUnderlined sequences in 25OVL-F, 25cOVL-F, and 31OVL-F correspond to
regions overlapping with 25OVL-R, 25cOVL-R, and 31OVL-R, respectively. cTarget
gene is the B. ovis gene to be deleted or PCR-amplified for the verification of
mutant strains. Primers Universal-F and Universal-R target pGEM-T Easy and its
derived recombinant plasmids at both sides of the cloned insert and were used
for sequencing of the DNA insert. The remaining primers target the B. ovis genome
and were designed according to the published genome sequence of B. ovis 63/290
(ATCC 25840) (accession numbers NC_009505 and NC_009504 for chromosome
I and II, respectively).
mutant strains was performed with specific PCRs targeting each
inactivated locus.
Growth Pattern, Autoagglutination, and
Susceptibility Assays
Growth characteristics of the mutant strains in TSA-YE-HS
plates and TSB-YE-HS liquid medium were compared to those
of parental B. ovis PA. Numbers of CFU/ml corresponding
to bacterial suspensions in PBS with optical density scores
at 600 nm (OD600) of 0.2 were determined for each mutant
by triplicate plating on TSA-YE-HS of the properly diluted
suspensions. The initial suspensions were prepared from bacteria
cultured in TSA-YE-HS plates for 44 h. Colony size was
photographed 5 days after plating and colonies enumerated
8 days after plating. Growth curves were established for triplicate
bacterial suspensions in TSB-YE-HS medium (30 ml) with
initial OD600 readings of 0.05 that were incubated at 37◦C
under agitation (120 rpm) and a 5% CO2 atmosphere. OD600
scores were measured through a 120-h period, and CFU/ml
numbers were evaluated at the beginning of the experiment
(t0), and after 24, 52, and 77 h of incubation (t24, t52, and
t77, respectively), by plating the properly diluted cultures on
TSA-YE-HS.
The autoagglutination assay was performed as described
previously (Caro-Hernández et al., 2007; Martín-Martín et al.,
2012) by measuring the evolution, over 48 h of static
incubation, of the OD600 values of bacterial suspensions
with initial readings of 0.8 (100% OD600) in TSB-YE-HS.
Susceptibility to 1 mg/ml of polymyxin B (Sigma-Aldrich,
St. Louis, MO, United States) and 0.1 mg/ml of sodium
deoxycholate (Sigma-Aldrich, St. Louis, MO, United States)
in PBS was expressed as the percentage of survival after
80 min of exposure. It was determined by comparison of
the numbers of CFU in untreated (incubation in PBS, 100%
survival) and treated bacterial suspensions (Caro-Hernández
et al., 2007; Martín-Martín et al., 2011). The results were
expressed as means ± standard deviation (SD) of three
assays.
Mapping of Cell Envelope Antigens
Reactivity of B. ovis mutants with MAbs specific for cell-
envelope antigens (Table 3) was measured by indirect
enzyme-linked immunosorbent assay (iELISA) as previously
described (Soler-Lloréns et al., 2014). MAbs specific for
Brucella peptidoglycan (PG), R-LPS, S-LPS, Omp2b, Omp10,
Omp16, Omp19, Omp25, Omp31, or periplasmic BP26 were
used (Cloeckaert et al., 1990, 1991, 1996a,b; Vizcaíno et al.,
2001b; Seco-Mediavilla et al., 2003). Briefly, 96-well plates
were coated overnight at room temperature with sonicated
(mild homogenization for 10 s at 40% intensity in a Sonic
Dismembrator model 120, Thermo Fisher Scientific, Waltham,
Ma, United States) bacterial suspensions in PBS (OD600 = 1),
TABLE 3 | Main characteristics of the monoclonal antibodies used in this work.
Monoclonal antibodya Specificity Abbreviation
A68/15B06/C08 Omp2b C08
A68/07G11/C10 Omp10 C10
A76/08C03/G03 Omp16 G03
A76/18B02/D06 Omp19 D06
A59/10F09/G10 Omp31 G10
A59/05F01/C09 Omp25 C09
A18/13D02/F05 Omp25 F05
A76/08H09/A02 Omp25 A02
V78/09B12/B02 BP26 B02
V78/02E08/F03 BP26 F03
V78/04D01/A10 BP26 A10
V78B/04G07/H05 BP26 H05
A76/03D06/A09 PG A09
A76/12G12/F12 S-LPS F12
A68/03F03/D05 R-LPS D05
aThe MAbs were obtained and characterized previously (Cloeckaert et al., 1990,
1991, 1992, 1996a,b; Zygmunt et al., 1994; Seco-Mediavilla et al., 2003).
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which were prepared from cultures in TSA-YE-HS plates. MAbs
(hybridoma supernatant) diluted 1/2 and a goat anti-mouse
IgG-horseradish peroxidase conjugate (Bio-Rad, Hercules,
CA, United States) diluted 1:9000 were used as primary and
secondary antibodies, respectively. Antigen–antibody binding
was revealed by incubation for 20 min with TMB as substrate
for peroxidase and subsequent addition of a 1 M HCl-based
stop solution (Interchim, Montluçon, France). The results were
expressed as means ± SD of the values recorded at 450 nm
(OD450) in a Labsystems Multiskan Ascent microplate reader
(Thermo Fisher Scientific) for three repeats by MAb and
strain.
Additionally, sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS–PAGE) and immunoblot were also
performed and carried out as previously described (Vizcaíno
et al., 2001b; Martín-Martín et al., 2009). Briefly, bacterial
suspensions concentrated to OD600 values of 20 were prepared
in H2O with the different B. ovis strains. They were submitted
to SDS–PAGE on a Protean II xi cell (Bio-Rad, Hercules,
CA, United States) and either stained with Coomassie blue
(Bio-Rad, Hercules, CA, United States) or transferred to a
nitrocellulose membrane in a semidry electroblotter (Amersham,
GE Healthcare, Little Chalfont, United Kingdom). Prestained
protein marker VI (Applichem-Panreac, Barcelona, Spain) was
used as protein standard. Nitrocellulose strips were saturated
with skim milk and then incubated with sera obtained, as
described before (Martín-Martín et al., 2009), by immunization
of rabbits with Omp31b, Omp25c, Omp25d, and Omp22 purified
recombinant proteins. Binding of the secondary antibody – a goat
anti-rabbit IgG-peroxidase conjugate (Sigma-Aldrich, St. Louis,
MO, United States) – was detected with a 4-chloro-1-naphthol
substrate solution.
Infection Assays on Murine Macrophage
and HeLa Cells
Infection assays of murine macrophage-like J774.A1 cells (DSMZ
ACC170) and epithelial HeLa (ATCC CCL-2TM) cells were
performed as described previously (Sidhu-Muñoz et al., 2016).
Briefly, 2× 104 J774.A1 macrophages or 1.5× 104 HeLa cells/well
were seeded on 96-well sterile microplates and incubated for 24 h
at 37◦C under a 5% CO2 atmosphere. After incubation for 2 h
with the B. ovis strains (4 × 106 CFU/well for macrophages or
8 × 106 CFU/well for HeLa cells) and killing of extracellular
bacteria by incubation with gentamycin for 1 h, intracellular
bacteria were enumerated in three wells per strain after lysis
of the phagocytes with H2O [t0 post-infection (p.i.)] (Sidhu-
Muñoz et al., 2016). The remaining wells were maintained in the
presence of gentamycin and intracellular bacteria were similarly
determined at 20 (t20) and 44 h (t44) p.i. The results were
expressed as means ± SD of the log CFU/well at each selected
p.i. time point (t0, t20, and t44) and are representative of at least
two experiments.
Mice and Ethics Statement
Female 6-week-old BALB/c mice (Charles River Laboratories,
Chatillon-sur-Chalaronne, France), received 1 week
previously, were used. They were randomly distributed
into experimental groups and kept with water and
food ad libitum in the animal experimentation facilities
of the University of Salamanca (registration number
PAE SA-001) or the Unidad de Producción y Sanidad
Animal, Instituto Agroalimentario de Aragón-IA2
(CITA-Universidad de Zaragoza) (registration number
ES502970012005).
Procedures with mice were designed according to Spanish
and European legislation regarding the use of animals in research
(RD 53/2013 and directive 2010/63/UE). Microbiological
practices and animal experimentation were approved by
the Biosecurity and Bioethics Committees of the University
of Salamanca, and authorized by the competent authority
of Junta de Castilla y León, Spain. The Animal Welfare
Committee of the CITA (Spain) also reviewed and approved the
protocols.
Virulence Assays and Antibody
Response in Mice
Preliminary evaluation of virulence in mice was performed
by intraperitoneal inoculation of 106 or 108 CFU/mouse
depending on the previous information about each single mutant
(Martín-Martín et al., 2012; Sidhu-Muñoz et al., 2016). One
mouse was used per strain, dose and time of analysis and
splenic colonization was evaluated 3 or 7 weeks (W3 and
W7) p.i. as described previously (Sancho et al., 2014). These
time points in parental B. ovis PA correspond to the acute
and chronic phase of infection, respectively (Caro-Hernández
et al., 2007; Martín-Martín et al., 2012; Sidhu-Muñoz et al.,
2016).
Spleen colonization of the selected mutants – according
to the results of the preliminary analysis – was evaluated at
W3 and W7 p.i. in mice inoculated intraperitoneally with
106 CFU, and at W1, W3, W5, W7, and W11 p.i. in mice
inoculated intraperitoneally with 108 CFU. Five mice per strain
and time point were used. The results were expressed as
means ± SD (n = 5) of the log of CFU/spleen for each
strain and time point. The identity of the recovered colonies
was checked by PCR. Antibodies specific for B. ovis PA were
determined by iELISA (Sancho et al., 2014) in sera obtained
from submandibular blood from the same mice. Briefly, a
suspension in PBS of heat-inactivated B. ovis PA whole cells
(OD600 = 1) was used as the coating antigen of 96-well plates and
a goat antimouse IgG-peroxidase conjugate (Sigma–Aldrich, St.
Louis, MO, United States) was used as the secondary antibody.
OD405 readings were recorded on a Multiskan Go Microplate
Reader (Thermo Fisher Scientific) after 30 min incubation
at room temperature with the substrate solution constituted
by 1 mM 2,2′-azino-di-(3-3-ethylbenzothiazoline-sulfonic acid)
(ABTS; Sigma-Aldrich, St. Louis, MO, United States) and
2 mM H2O2 (Sigma-Aldrich, St. Louis, MO, United States)
in 0.1 M citrate, pH 4.2. Antibody titers in serum were
defined as the inverse of the highest serum dilution scoring
an OD405 value twice as high as that obtained with the blank
(mean OD405 of six wells in which serum was replaced by
dilution buffer). The results were represented as means ± SD
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of the log of the titers obtained with five mice analyzed
individually.
Vaccine Efficacy and Immune Response
of B. ovis 1omp101ugpB1omp31
BALB/c mice were inoculated intraperitoneally with PBS,
105 CFU of the classical vaccine B. melitensis Rev1, or 108 CFU
of the attenuated mutant B. ovis 1omp101ugpB1omp31. Seven
weeks later, corresponding with the time point where the B. ovis
vaccine was cleared from spleen, five mice per group were either
challenged with 2 × 105 CFU of B. ovis PA, or processed for the
evaluation of the antibody and cellular immune responses specific
for B. ovis PA. Determination of virulent B. ovis PA in spleen
was evaluated 3 weeks after experimental challenge (Sancho et al.,
2014). The CFU number of virulent B. ovis PA in mice vaccinated
with B. melitensis Rev 1 was obtained by subtracting the values
obtained in TSA-YE-HS-Strep medium from those obtained in
the same medium without antibiotic. Results were expressed as
means ± SD (n = 5) of the log CFU/spleen of B. ovis PA for each
vaccination group.
IgG titers in serum were analyzed, as described above, in
five mice per group 7 weeks after vaccination by using heat-
inactivated B. ovis PA whole cells as the coating antigen in a
iELISA test. Additionally, IgG isotypes were determined under
the same conditions but using goat anti-mouse IgG1-, IgG2a-, or
IgG2b-peroxidase conjugates (Santa Cruz Biotechnology, Dallas,
TX, United States). The same mice were processed as previously
described (Sancho et al., 2014) to evaluate the cytokine response
of splenocytes to a second stimulus with B. ovis PA. Briefly, spleen
cells from immunized mice were cultured in 24-well sterile plates
and stimulated by exposure to heat-inactivated (1 h at 65◦C)
B. ovis PA whole cells (107 CFU/well), 10 µg/ml of the mitogen
concanavalin A (Sigma-Aldrich, St. Louis, MO, United States)
as a positive control of cell proliferation, or culture medium
as a negative control. After 72 h of incubation, the culture
supernatants were harvested to evaluate the levels of interferon-γ
(IFN-γ), tumor necrosis factor-α (TNF-α), IL-10, and IL-12(p40).
They were determined by sandwich ELISA with OptEIATM
Mouse Sets specific to each cytokine, as instructed by the
manufacturer (BD Biosciences, San Diego, CA, United States).
Two wells were used for each experimental condition and
mouse. The results for each vaccination group were expressed as
means± SD of the cytokine amount (ng/well) in the supernatants
of splenocytes obtained from five individual mice. The results
obtained with the positive and negative controls (concanavalin
A and RPMI as stimulating agents, respectively) were as expected
and are not shown.
Statistical Analysis
Statistical comparisons between means were performed using
analysis of variance. The significance of the differences (P< 0.05)
between the experimental groups was determined with the
post hoc Fisher’s protected least significant differences (PLSD)
test. To simplify the figures and tables, no ranking of P-values
has been established and all significant differences are marked as
P < 0.05.
RESULTS
Genotypic Characterization of the
Mutants
The B. ovis mutants (Table 1) were genotypically characterized
as described in the section “Materials and Methods.” Two PCR
reactions were settled for each inactivated gene, one reaction
with external primers to each side of the deleted locus (amplified
fragment of lower size in mutant strains than in parental strain),
and a second reaction with an external primer to the deleted
loci and a primer annealing inside the deleted region (no
amplification in mutant strains). All single and multiple mutants
gave the expected results for each inactivated gene (data not
shown).
Although not all combinations of single genes shown in
Table 1 were tempted in multiple mutants, two combinations
were specially assayed without success: a double mutant in
lipoproteins Omp10 and Omp19 and a double mutant in
major Omp25 and Omp31 proteins. Despite multiple attempts,
the intermediate strains for these double mutants always
reverted to the single mutant initial genotype. Similarly,
two independent omp25c intermediate strains always reverted
to the parental genotype and, consequently, the non-polar
1omp25c single mutant was not obtained. However, the non-
polar deletion of omp25c, with plasmid pNV25cOVL02, was
successful in the 1omp251omp25c double mutant and in the
1omp101omp311omp25c and1omp311omp101omp25c triple
mutants. The1omp25c-k mutant, where omp25c was replaced by
a kanamycin resistance cassette (Caro-Hernández et al., 2007),
was used in this work for comparisons with the non-polar
1omp25c double and triple mutants.
Growth Characteristics of the Mutants
The numbers of CFU in bacterial suspensions with OD600
values of 0.2 were determined for each mutant in TSA-YE-
HS plates. Bacterial counts obtained for 1omp25, 1bepC,
1ugpB, and1bacA single mutants and for1bepC1ugpB double
mutant did not significantly differ from those observed with the
parental strain. On the contrary,1omp31,1omp25c-k,1omp10,
1omp19, 1cgs, and the remaining multiple mutants showed, in
different degrees, lower CFU values than B. ovis PA (Table 1).
The 1omp311cgs double mutant and its derived triple mutants,
the 1omp251cgs mutant and the 1omp101omp311omp25c
and 1omp311omp101omp25c triple mutants (bearing the same
three genes inactivated but in a different order) showed the lowest
CFU/ml values in TSA-YE-HS plates (Table 1). The numbers of
CFU/ml obtained for each mutant were used for the calculation
of the bacterial doses in further experiments.
In addition, the size of the colonies in TSA-YE-HS was
monitored over time and recorded 5 days after inoculation (see
some representative results in Figure 1A). Colony size of the
1omp25, 1bacA, 1bepC, 1ugpB, 1omp25c-k, 1bepC1ugpB,
and 1omp251omp25c mutants was undistinguishable from that
of the parental strain (see B. ovis PA and the 1omp251omp25c
mutant in Figure 1A). Growth of the 1omp10 and 1omp19
mutants was slightly delayed when compared to the parental
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FIGURE 1 | Growth pattern of B. ovis PA and selected mutants in TSA-YE-HS (A) and TSB-YE-HS (B,C). Colony size in TSA-YE-HS (A) was photographed 5 days
after inoculation. Plates were taken in the same picture and a section of each strain was extracted to compose the final panel. Growth in TSB-YE-HS liquid medium
was determined by the evolution with time of the OD600 values (B) and of the bacterial CFU/ml numbers (C). The SD of three assays, which was always lower than
5% of the mean, is not shown. To simplify the figure, relevant statistically significant differences (P < 0.05) are mentioned in the text.
strain but the initial differences in colony size were not apparent
after 5 days of incubation (data not shown). Colonies of the
1omp31 and 1cgs single mutants appeared hardly visible 72 h
after inoculation, 24 h later than those of the B. ovis PA
parental strain, and were smaller than those of the parental
strain after 5 days (see 1omp31 in Figure 1A). A similar or
higher delay, depending on the strain, was detected with colonies
of their multiple mutants. Despite the triple gene deletion,
the 1omp101ugpB1omp31 mutant showed a colony growth
pattern undistinguishable from that of the single1omp31 mutant
(Figure 1A). The most important growth defects were observed
with the 1omp311cgs mutant and its derived triple mutants
(with the additional deletion of omp10 or omp19), whose colonies
started to be detected 96 h after inoculation and showed the
smallest size after 5 days of incubation (Figure 1A). Colonies of
the 1omp101omp311omp25c and 1omp311omp101omp25c
triple mutants were also detected after 96 h of incubation but,
at day 5 post-inoculation, they were bigger (see colonies of the
1omp101omp311omp25c mutant that are representative for
both mutants) than those of B. ovis1omp311cgs (Figure 1A).
The 1omp311cgs, 1omp101omp311omp25c, and
1omp101ugpB1omp31 mutants (selected according to the
results obtained in the evaluation of virulence described below),
the 1omp251omp25c mutant (selected because it lacks two
major OMPs in B. ovis PA) and their corresponding single
mutants were also analyzed regarding growth in TSB-YE-HS
liquid medium (Figures 1B,C). Cultures were adjusted to
OD600 values of 0.05 and incubated at 37◦C under agitation
(120 rpm) and a 5% CO2 atmosphere. As expected, according
to the correlation OD600-CFU/ml in solid medium previously
determined, values of CFU/ml at t0 for mutants with inactivated
omp31 or cgs were lower than those of B. ovis PA (P < 0.05),
the 1omp311cgs and 1omp101omp311omp25c mutants
presenting the lowest values (P < 0.05) (Figure 1C). However,
the CFU/ml values of the 1omp31 and 1omp101ugpB1omp31
mutants at the beginning of the stationary phase (approximately
t52) were similar to those of B. ovis PA (P > 0.05), which
correlates with the higher OD600 scores observed with these
mutants by this time (P < 0.05). Although the 1omp311cgs and
1omp101omp311omp25c mutants, those showing the most
important growth defects in solid medium (Figure 1A), also had
higher OD600 values at this moment (P < 0.05), their CFU/ml
counts never reached the maximum level of B. ovis PA (detected
at t52) (Figures 1B,C). The 1cgs, 1omp25, 1omp25c-k, and
1omp251omp25c mutants had slightly higher OD600 scores in
the stationary phase, when compared to the parental strain, but
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not important differences in the CFU/ml values (Figures 1B,C
and data not shown). The 1omp10 and 1ugpB mutants behaved
similarly to the parental strain (data not shown).
Virulence in the Mouse Model
For a preliminary assay of virulence, aiming to select the
most relevant mutants, mice were inoculated with 106 CFU
of the parental strain or its derived mutants and bacteria
were enumerated in spleen at W3 and W7 p.i. The multiple
cgs mutants were excluded from this first analysis, since
the single 1cgs mutant showed poor spleen colonization
in a previous study (Martín-Martín et al., 2012). Only
those mutants that, when compared to the parental strain,
showed bacterial counts lower than 1.5 logarithmic units
were considered as probably attenuated and they were later
inoculated in a dose of 108 CFU/mouse. Uniquely the
1cgs, 1omp101ugpB1omp31, 1omp101omp311omp25c, and
1omp311omp101omp25c mutants met this requirement and,
together with the 1cgs multiple mutants, were evaluated with
the increased dose (except B. ovis1omp311omp101omp25c that
bears the same mutations as the 1omp101omp311omp25c but
in a different order). All these mutants were present in spleen at
W3 p.i. but the CFU were between 1 and 2.5 log units lower than
those obtained with the parental strain (Table 1). All cgs mutants
and B. ovis1omp101omp311omp25c had similar splenic counts
at W7 p.i., which were not drastically different from those
observed at W3 p.i., while the 1omp101ugpB1omp31 mutant
was not detected in spleen at W7 p.i. (Table 1).
According to these results, the 1omp311cgs, 1omp10
1ugpB1omp31, and 1omp101omp311omp25c mutants were
retained for a detailed evaluation of virulence and the selection
of vaccine candidates. First, to statistically verify the previous
results, the spleen colonization was evaluated in five mice per
group at W3 and W7 after intraperitoneal infection with 106 CFU
(Figure 2A). The spleen weight (Figure 2B) and the levels in
serum of IgG reacting against B. ovis PA whole cells (Figure 2C)
were also determined. As expected, spleen infection of B. ovis
PA was noteworthy at both sampling points – with mean values
ranging between log 6 and 7 of CFU/spleen – while the three
mutants presented a poor colonization under these conditions
(Figure 2A). Spleen infection of the mutants was undetectable
in several mice per group, although two out five mice inoculated
with the 1omp101omp311omp25c mutant gave values of about
log 5 CFU/spleen at W7 p.i. (Figure 2A). Spleen weight and IgG
titers in serum were also significantly higher (P < 0.05) in mice
inoculated with the parental strain (Figures 2B,C).
The same parameters described above were evaluated at
several time points over a 11-week period in mice inoculated
with 108 CFU of each strain (Figures 2D–F), the dose usually
employed for evaluation of attenuated strains as vaccines (Sancho
et al., 2014; Soler-Lloréns et al., 2014; Silva et al., 2015b). The
parental strain showed high levels of spleen infection through the
entire experiment with mean log CFU/spleen values of 5.99 at W1
p.i. and a peak at W3 p.i. of 7.64. B. ovis PA counts decreased
thereafter but were still high at the end of the experiment
(mean log CFU/spleen values of 5.01 at W11) (Figure 2D). The
1omp311cgs and 1omp101omp311omp25c mutants displayed
lower levels of splenic infection at W1, with mean CFU/spleen
values 1–1.5 log lower than those of the parental strain (P< 0.05).
However, although their maximum CFU/spleen scores (about
log 6 at W3–W5 p.i.) did never reach those of B. ovis PA (log
7.64 at W3 p.i.), they persisted in spleen with similar values to
those of the parental strain at W11 p.i. (P > 0.05) (Figure 2D).
The spleen colonization of the 1omp101ugpB1omp31 mutant
did not show statistically significant differences with the parental
strain at W1 p.i., but the bacterial counts did not increase at W3
p.i. and decreased thereafter until the detection limit of infection
at W7 p.i. (P < 0.05) (Figure 2D).
At W1 p.i., the spleen weight in mice infected with 108 CFU
of the parental strain (0.102 ± 0.030 g) was analogous to that
currently obtained with mice inoculated with PBS and that was
also observed in the PBS group used to determine the production
of cytokines by splenocytes in the experiment described below
(0.096± 0.005 g) (P> 0.05). However, a prominent splenomegaly
was detected at W3 p.i. (0.478± 0.020 g/spleen) which, although
decreased after W3 p.i., persisted until the end of the experiment
(0.205 ± 0.046 g/spleen) (P < 0.05) (Figure 2E). On the
contrary, the B. ovis mutants did never reach mean values of
0.200 g/spleen (Figure 2E). At W1 p.i., all groups of mice had
low levels of IgG reactive with whole cells of B. ovis PA. An
important increase of the antibody response was detected at W3
p.i. in all groups (P < 0.05), except in mice vaccinated with
the 1omp311cgs mutant (P > 0.05). At W5 p.i. and thereafter,
mice inoculated with the parental strain or the1omp311cgs and
1omp101omp311omp25c mutants displayed IgG titers of about
log 4, while mice inoculated with B. ovis1omp101ugpB1omp31
gave titers in the order of 0.5 logarithmic units higher (P < 0.05)
than those detected in the B. ovis PA group (Figure 2F).
Autoagglutination and Susceptibility
Assays
In addition to the three selected mutants, other relevant
mutants were included in the remaining studies by their interest
to increase the knowledge about the B. ovis cell envelope.
Several tests related to the OM properties of Brucella spp.
(i.e., autoagglutination and resistance to polymyxin B and
sodium deoxycholate) (Martín-Martín et al., 2011; Vizcaíno
and Cloeckaert, 2012) were performed. In the autoagglutination
assay, most of the single mutants behaved as the B. ovis PA
parental strain (P > 0.05), remaining in suspension until the
end of the experiment (Figure 3 and data not shown). The
exceptions were B. ovis 1omp31 – with %OD600 values of
about 30 and 10% after 24 and 48 h of static incubation,
respectively – and the 1cgs and 1omp25c-k mutants, whose
%OD600 values gradually decreased until 70% at the end of
the experiment (P < 0.05 when compared to the parental
strain) (Figure 3). The omp31multiple mutants behaved similarly
to the single mutant, although the 1omp101omp311omp25c
and 1omp311omp101omp25c mutants agglutinated more
quickly (they were almost completely settled after 10 h)
(P < 0.05) (Figure 3). B. ovis 1omp251cgs behaved like
the single 1cgs mutant while B. ovis 1omp251omp25c did
not show differences with the parental strain (P > 0.05)
(Figure 3).
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FIGURE 2 | Bacterial spleen colonization (A,D), spleen weight (B,E), and IgG response in serum against B. ovis PA whole cells (C,F) in BALB/c mice. Mice (n = 5
per group and time point) were inoculated intraperitoneally with 106 (upper panels) or 108 (lower panels) CFU/mouse of B. ovis PA or 1omp311cgs,
1omp101ugpB1omp31, and 1omp101omp311omp25c mutants. Statistically significant differences in upper panels, compared to parental B. ovis PA, are
marked with an asterisk. To simplify the figure, relevant statistically significant differences in lower panels (P < 0.05) are mentioned in the text. Detection limit for
antibody titers is log 1.7. As a reference for panels B and E, spleen weight of mice inoculated with PBS (n = 5) for the protection experiment described in Figure 8
was 0.096 ± 0.005 (W7 post-inoculation).
FIGURE 3 | Autoagglutination assay with bacterial suspensions of initial OD600 readings of 0.8 (100% OD600). The percentage of the OD600 values was determined
over 48 h of static incubation. Panels A and B represent results of two independent experiments. The SD of three assays, which was always lower than 5% of the
mean, is not shown. To simplify the figure, relevant statistically significant differences (P < 0.05) are mentioned in the text.
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Brucella ovis 1bacA and the B. ovis 1bacA1omp31 double
mutant were more resistant than B. ovis PA to polymyxin
B exposure for 80 min (Table 4). On the contrary, B. ovis
1omp251omp25c, and the 1omp31 single and multiple
mutants – except the previously mentioned 1bacA1omp31
mutant – showed higher susceptibility to polymyxin B
than the parental strain (Table 4). The lowest survival
percentages were obtained with the 1omp101omp311omp25c
and 1omp311omp101omp25c mutants (less than 10%
survival). Only the 1omp311cgs double mutant and its derived
1omp311cgs1omp10 and 1omp311cgs1omp19 triple mutants
were more susceptible to sodium deoxycholate than the parental
strain (about 30% survival versus 86% survival, respectively)
(Table 4).
Mapping of Cell Envelope Antigens
The reactivity of the B. ovis mutants with MAbs raised against
Brucella S-LPS, R-LPS, PG, major and minor OMPs, and
periplasmic BP26 was analyzed by iELISA (Figure 4 and data
not shown). As expected, the MAb-specific against S-LPS did
TABLE 4 | Susceptibility of B. ovis PA and selected mutants to polymyxin B and
Na deoxycholate.
% Survival after exposure toa:
Brucella ovis strainsb Polymyxin B
(1 mg/ml)
Na deoxycholate
(0.1 mg/ml)
B. ovis PA 69.03 ± 6.12 86.25 ± 5.74
Single mutants
1omp31 27.47 ± 3.04∗ 83.74 ± 3.09
1omp25 65.84 ± 7.17 92.94 ± 4.06
1omp25c-k 65.99 ± 4.72 95.89 ± 7.15
1cgs 77.96 ± 11.80 79.82 ± 9.07
1bacA 84.10 ± 5.49∗ 87.38 ± 8.28
1omp10 62.04 ± 3.46 91.20 ± 4.22
1omp19 67.27 ± 7.05 83.19 ± 7.75
1ugpB 77.59 ± 11.67 90.66 ± 9.42
Double mutants
1omp311omp19 25.68 ± 2.94∗ 90.49 ± 7.79
1omp311ugpB 20.66 ± 0.57∗ 92.65 ± 3.64
1omp311cgs 31.20 ± 14.30∗ 32.14 ± 1.27∗
1omp251cgs 61.71 ± 7.30 92.35 ± 5.18
1omp251omp25c 45.23 ± 5.10∗ 91.36 ± 9.59
1omp101omp31 33.31 ± 4.58∗ 84.66 ± 6.36
1omp101ugpB 64.22 ± 5.36 77.93 ± 9.26
1bacA1omp31 88.06 ± 18.61∗ 86.90 ± 5.51
Triple mutants
1omp101ugpB1omp31 30.50 ± 9.94∗ 88.52 ± 6.22
1omp101omp311omp25c 1.65 ± 0.36∗ 76.74 ± 9.37
1omp311omp101omp25c 7.19 ± 4.38∗ 80.40 ± 7.49
1omp311cgs1omp10 37.84 ± 9.43∗ 33.63 ± 1.78∗
1omp311cgs1omp19 33.30 ± 3.68∗ 34.39 ± 2.94∗
aResults are expressed as the mean ± SD of three assays. Statistically significant
differences (P< 0.05), compared to the parental strain, are marked with an asterisk.
bSee legend to Figure 1 for strain characteristics.
not react with any mutant or with the parental strain (data not
shown) and omp31, omp25, omp10, or omp19 single and multiple
mutants did not react with the respective MAbs (see Figure 4
for representative results). No relevant differences were observed
between the parental strain and the mutants regarding reactivity
with MAbs specific against Omp31 (except with mutants lacking
omp31), Omp10 (except with mutants lacking omp10), Omp16,
Omp2b, PG, and R-LPS. On the contrary, all omp31 mutants
showed a stronger reaction with MAb C09 (specific against
Omp25) and omp19 mutants showed a stronger reaction with
MAb B02, specific against BP26 (Figure 4, upper panels and data
not shown). Accordingly, several omp31 mutants were tested in
iELISA with three MAbs specific against Omp25, while omp19
mutants were tested with four anti-BP26 MAbs. All the 1omp31
and1omp19 mutants showed a stronger reactivity with the anti-
Omp25 and anti-BP26 MAbs, respectively (Figures 4G,H), which
confirmed the results obtained in the previous analysis.
The protein profile of the most relevant strains was
evaluated by SDS–PAGE followed by Coomassie blue straining
(Figure 5A). Proteins were also transferred to nitrocellulose to
assess the reactivity with sera raised against the proteins of the
Omp25/Omp31 family. A serum against Omp25c was used to
detect both Omp25c and Omp25 since these proteins display
cross-reacting epitopes (Martín-Martín et al., 2009), while the
detection of Omp31 was performed with a serum raised against
Omp31b (an OMP absent in B. ovis) that strongly cross-react with
Omp31 (Martín-Martín et al., 2009). Omp25d and Omp22 were
detected by reactivity with their respective anti-sera (Martín-
Martín et al., 2009).
A multiple band pattern, dependent on the electrophoretic
conditions, is frequently observed in SDS–PAGE for Omp25,
Omp25c, and Omp31 (Cloeckaert et al., 1990; Martín-Martín
et al., 2009). Two protein bands corresponding to Omp25c
were detected by immunoblot in parental B. ovis PA and were
absent in all omp25c mutants (Figure 5B). Additionally, the
intensity of the upper band in omp31 mutants was higher than
that observed with the parental strain (Figure 5B). Absence
of the lower band of Omp25c in the 1omp25c mutants
was also evident in the SDS–PAGE gel (Figure 5A, lanes
1omp25c-k, 1omp25Domp25c, and 1omp101omp311omp25c)
while the absence of the upper band was only apparent in the
1omp101omp311omp25c triple mutant (Figure 5A). This result
can be explained by the fact that this mutant also lacks Omp31,
which is a major OMP that exhibits an electrophoretic mobility
similar to that of Omp25c (Figure 5A) and, consequently, masks
the absence of the upper Omp25c band in the other 1omp25c
mutants.
Omp25 was detected between the two Omp25c bands except
in the omp25 mutants. Absence of Omp25 in these mutants
was evidenced in both the SDS–PAGE gel (Figure 5A) and
the immunostained nitrocellulose (Figure 5B) (see 1omp25,
1omp251cgs, and 1omp251omp25c lanes in comparison
with PA lanes). With both techniques, the Omp25 band
of the 1omp31 mutants was more intense than in B. ovis
PA. Omp31 was detected in immunoblot and with the
same intensity in all the strains, except those lacking the
encoding gene (Figure 5C). Absence of Omp31 in these latter
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FIGURE 4 | Reactivity by iELISA of MAbs against cell envelope antigens with B. ovis PA and selected mutants. The reactivity of MAbs specific against PG, R-LPS,
the BP26 periplasmic protein, the Omp2b, Omp31, and Omp25 major OMPS, and the Omp10, Omp16, and Omp19 OM lipoproteins (A–F) was tested with most of
the mutant strains obtained in this work. Representative results are shown in panels A–F and others are commented in the text. Differences between the mutant
strains and the parental strain were considered relevant for further analysis when, in addition to being statistically significant (P < 0.05), the mean values differed
more than 25% (marked with an asterisk). Reactivity of 1omp31 single and multiple mutants with several anti-Omp25 MAbs (G), and of 1omp19 mutants with
several anti-BP26 MAbs (H), is also shown. Statistically significant differences between the mutant strains and the parental strain (P < 0.05) in panels G and H, are
marked with an asterisk.
mutants was also evident in the SDS–PAGE gel (Figure 5A).
The Omp22 band was revealed in B. ovis PA and the
analyzed mutants, while Omp25d – that has only been
observed in a complemented mutant overexpressing the protein
(Martín-Martín et al., 2009) – was not detected (data not
shown).
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FIGURE 5 | Profiles of B. ovis PA and selected mutants in SDS–PAGE (A) and immunoblot with sera of rabbits immunized with purified recombinant Omp25c (B) or
Omp31b (C). The prestained protein marker VI (Applichem-Panreac) is shown in (A) and positions of known OMP bands are marked with arrows (A–C).
Cellular Models of Infection
The intracellular behavior of B. ovis PA and the most relevant
mutants was evaluated in J774.A1 murine macrophages and
HeLa cells. No significant differences between strains (P > 0.05)
were observed regarding internalization in J774.A1 macrophages
(Figure 6, upper panels). However, although the intracellular
bacterial numbers decreased at t20 with all the strains, the
reduction was more pronounced with strains 1omp251omp25c
(Figure 6A), 1omp251cgs, 1omp311cgs, and its derived triple
mutants (Figure 6C), and with B. ovis 1omp101ugpB1omp31
and1omp101omp311omp25c (Figure 6B) (P< 0.05). After this
moment, all strains were able to replicate, reaching intracellular
CFU numbers at t44 about 1 log unit higher than those
detected at t20 for each strain (P < 0.05) (Figure 6, upper
panels).
In HeLa cells, the 1omp25c mutants (1omp25c-k,
1omp251omp25c, 1omp101omp311omp25c, and 1omp31
1omp101omp25c) showed a deficient internalization, with
intracellular CFU at t0 in the order of 1–1.5 log units lower than
those determined for B. ovis PA (P < 0.05). On the contrary,
all mutants bearing the omp31 deletion, except those with
the 1omp25c genotype (B. ovis 1omp101omp311omp25c and
1omp311omp101omp25c), showed an increased internalization
in HeLa cells, with CFU at t0 about 1 log higher than those of
the parental strain (P < 0.05) (Figure 6, lower panels).
All strains suffered a reduction (P < 0.05) of intracellular
CFU a t20 while at t44 the bacterial numbers were, in
general, similar to those obtained at t20 (Figure 6, lower
panels).
Searching for an explanation to the internalization differences
observed in HeLa cells, the 1omp25c-k mutant complemented
with the wild-type gene and the 1omp31-k mutant together
with its complemented strain (Caro-Hernández et al., 2007)
were also analyzed regarding internalization in HeLa cells (CFU
determined at t0) and their behavior in immunoblot with sera
reacting with Omp31 and Omp25c (Figure 7). Complementation
of the 1omp25c-k mutant restored its ability to enter HeLa
cells like the parental strain (Figure 7A) and the production of
Omp25c (Figures 6B,C). The complemented 1omp31-k mutant
recovered the ability to produce Omp31, but its level was
lower than that of the parental strain (Figures 7B,D). This fact
was concomitant with a higher intensity of Omp25c bands,
when compared to B. ovis PA that, however, did not reach the
intensity observed with the 1omp31 and 1omp31-k mutants
(Figure 7C). Internalization of the complemented 1omp31-k
mutant in HeLa cells was similar to that of the 1omp31 mutant
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FIGURE 6 | Internalization and intracellular behavior of B. ovis PA and selected mutants in J774.A1 murine macrophages (A–C) and HeLa cells (D–F). The results
are expressed as the means ± SD (n = 3) of the log CFU/well at each time point. To simplify the figure, relevant statistically significant differences (P < 0.05) are
mentioned in the text.
and significantly higher than that observed with the parental
strain (Figure 7A).
Efficacy as Vaccine of B. ovis
1omp101ugpB1omp31
The usefulness as vaccine of B. ovis 1omp101ugpB1omp31
against B. ovis PA was evaluated in mice and compared to
that of the B. melitensis Rev1 heterologous vaccine. Spleen
colonization of the challenge strain was evaluated 3 weeks after
infection (Figure 8F) and the humoral (Figure 8E) and cellular
(Figures 8A–D) immune response was evaluated at the time
point selected for the challenge with the virulent strain (W7
post-vaccination).
Weight of spleens obtained at W7 post-vaccination from
mice inoculated with the 1omp101ugpB1omp31 mutant
(0.104± 0.012 g) did not show statistically significant differences
with that of mice inoculated with PBS (0.096 ± 0.005 g),
while splenomegaly (P < 0.05) was detected in mice
vaccinated with B. melitensis Rev1 (0.136 ± 0.011 g) (data
not shown). Additionally, B. melitensis Rev1 was detected
in spleen (log CFU/spleen values of 3.66 ± 0.07), while the
1omp101ugpB1omp31 mutant was cleared by this time (data
not shown).
Splenocytes were stimulated with B. ovis PA whole cells to
evaluate, by specific ELISA tests, the production of cytokines.
Splenocytes of mice inoculated with PBS secreted limited
amounts of IFN-γ, while about 30 and 60 times higher levels
(P < 0.05) were detected in the groups vaccinated with
the 1omp101ugpB1omp31 mutant and B. melitensis Rev1,
respectively (Figure 8A). In a lesser extent, splenocytes from
vaccinated mice also produced more IL-10 (P < 0.05) than
those obtained from mice of the PBS group (mean values
of 14.7, 9.9, and 1.4 ng/well for the B. melitensis Rev1,
B. ovis 1omp101ugpB1omp31, and PBS groups, respectively)
(Figure 8C). Regarding the production of TNF-α, splenocytes
from mice vaccinated with the two Brucella attenuated strains
secreted about double amounts (mean values of 3 ng/well)
than those obtained from the unvaccinated control group
(P < 0.05) (Figure 8B). No statistically significant differences
were observed between groups concerning the production of
IL-12(p40) (Figure 8D).
At the time of challenge, mice inoculated with PBS 7 weeks
earlier showed low titers (close to the detection limit of log 1.7)
of serum antibodies of the IgG1, IgG2a, and IgG2b subclasses able
to react with B. ovis PA whole cells in iELISA (Figure 8E). On the
contrary, mice vaccinated with B. ovis 1omp101ugpB1omp31
had titers of the three IgG subclasses (ranging from log
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FIGURE 7 | (A) Internalization in HeLa cells of parental B. ovis PA, the 1omp25c and 1omp31 mutants and mutant strains complemented with wild-type omp25c
or omp31. SDS–PAGE profiles (B) and immunoblot detection of Omp25, Omp25c (C), and Omp31 (D) in the same strains. Strains 1omp31-k and 1omp25c-k
were previously obtained by replacement of omp31 or omp25c by a kanamycin-resistance cassette (Caro-Hernández et al., 2007). They were complemented with
the corresponding wild-type genes to give strains identified as 1omp31-k com and 1omp25c-k com, respectively (Caro-Hernández et al., 2007). The prestained
protein marker VI (Applichem-Panreac) is shown in (B) and positions of known OMP bands are marked with arrows. Statistically significant differences when
compared to the parental strain are marked with an asterisk.
3.99 ± 0.16 for IgG2b to log 4.65 ± 0.13 for IgG1) that were
about 1.5 log units higher (P < 0.05) than those detected in
mice vaccinated with the B. melitensis Rev1 heterologous vaccine.
Within each vaccination group, no relevant differences were
observed between the three IgG subclasses (Figure 8E).
The homologous B. ovis 1omp101ugpB1omp31 vaccine
was not detected in spleen 3 weeks after the experimental
challenge while it prevented spleen colonization of virulent
B. ovis PA (CFU/spleen counts were under the detection
limit) (Figure 8F). When compared to control mice inoculated
with PBS, vaccination with heterologous B. melitensis Rev1
also drastically reduced the spleen colonization of B. ovis PA
(Figure 8F), but both the vaccine strain and the challenge strain
were detected in some mice.
DISCUSSION
With the aim to increase our knowledge about the OM and
virulence of B. ovis and to develop a specific homologous
attenuated vaccine, multiple deletion mutants targeting nine
genes related to the OM were obtained and characterized. Two
of these genes encode Omp10 and Omp19, two lipoproteins
that are conserved in Brucella (Cloeckaert et al., 1990; Tibor
et al., 1994, 1996) and have orthologs in other phylogenetically
related bacteria able to establish interactions with eukaryotic
cells either as symbionts or as pathogens (e.g., Ochrobactrum,
Bartonella, Rhizobium, Ensifer, Sinorhizobium) (Cloeckaert et al.,
1999; Barquero-Calvo et al., 2009). This observation suggests
their relevant role for the bacterium and, in fact, both lipoproteins
have been linked to the virulence of B. abortus 544 (Tibor et al.,
2002). Surprisingly, the individual absence of Omp10 and Omp19
in the OM of B. ovis PA did not affect its virulence or modified
notably its OM-related properties (Sidhu-Muñoz et al., 2016). On
the contrary, the multiple assays we have performed to achieve
the simultaneous deletion of omp10 and omp19 in B. ovis PA
were unsuccessful. Since OM lipoproteins are thought to anchor
the OM through the lipid moiety and contribute to the stability
of the cell envelope (Goolab et al., 2015), Omp10 and Omp19
could have an interchangeable role necessary to maintain the OM
integrity. Nevertheless, the amount of Omp10 in B. ovis1omp19
and the amount of Omp19 in the 1omp10 mutant does not
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FIGURE 8 | Cytokine secretion by stimulated splenocytes (A–D), levels in
serum of IgG subclasses reactive with B. ovis PA whole cells (E), and
protective efficacy against B. ovis PA infection (F) in mice vaccinated with
B. ovis 1omp101ugpB1omp31 or B. melitensis Rev1 and in mice inoculated
with PBS. Splenocytes (A–D) and sera (E) were obtained 7 weeks after
inoculation (five mice per group). At that time, five mice per group were
inoculated with virulent B. ovis PA and bacterial colonization of spleen was
determined 3 weeks later to evaluate the protective efficacy of the
vaccines (F). Splenocytes were stimulated with heat-killed B. ovis PA whole
cells for 72 h (A–D) before the evaluation of secreted cytokines. Statistically
significant differences, compared to mice inoculated with PBS, are marked
with an asterisk. Statistically significant differences of the 1omp101ugpB
1omp31 group compared to the B. melitensis Rev1 group are marked with
an asterisk in brackets.
seem to be increased (Figure 4B and data not shown), although
the absence of one of these lipoproteins, in the presence of the
other, could also be compensated by an increase in other cell
envelope proteins. In this respect, a higher reactivity with MAbs
against BP26 suggestive of increased levels of this periplasmic
protein was detected in the mutants bearing the omp19 deletion
(Figure 4H). Contrasting with the impossibility to obtain the
double 1omp101omp19 mutant, the simultaneous absence of
major Omp31 together with Omp10 or Omp19 lipoprotein was
well tolerated in B. ovis PA, since the respective double mutants
do not have prominent defects in virulence (Table 1) and the
other phenotypic changes are associated to the deletion of omp31
(Table 4, Figures 3, 5, 6, and data not shown). Similarly, deletion
of ugpB on the 1omp10 or 1omp19 genetic background did not
affect the virulence (Table 1), and the alterations detected after
deletion of cgs on the same mutants resembled those detected
with the B. ovis1cgs single mutant (Table 1).
Other target surface antigens were Omp31, Omp25, and
Omp25c that are abundant OMPs in B. ovis (Cloeckaert et al.,
2002; Martín-Martín et al., 2009; Vizcaíno and Cloeckaert, 2012)
and the main members of the Omp25/Omp31 family that is
constituted by seven homologous OMPs (Salhi et al., 2003;
Vizcaíno et al., 2004; Vizcaíno and Cloeckaert, 2012). Orthologs
of this family of OMPs have been found in Bartonella quintana
(Minnick et al., 2003) and other Rhizobiales (e.g., Rhizobium
leguminosarum, Agrobacterium tumefaciens, or O. anthropi),
which suggests that the redundancy of these OMPs provides an
advantage that could be related with the compensatory effect
between these proteins previously reported (Salhi et al., 2003;
Caro-Hernández et al., 2007; Martín-Martín et al., 2009; Vizcaíno
and Cloeckaert, 2012). This compensatory effect is in accordance
with the apparent increase of Omp25 and Omp25c that was
observed with all omp31 mutants, except those also lacking
omp25c where Omp25c was not detected (Figures 4, 5). On
the contrary, omp25 and omp25c mutants and even the double
1omp251omp25c mutant did not show higher levels of Omp31
(Figures 4, 5). In addition, this latter double mutant did not
suffer important defects regarding in vitro growth (Figure 1)
or virulence in mice (Table 1). These observations could be
indicative of a more relevant role for Omp31, whose absence in
the OM would require a compensation with another paralog that
would not be necessary when Omp25 or Omp25c are missing.
However, considering that our attempts to obtain a B. ovis PA
double mutant defective in Omp31 and Omp25 were fruitless,
it seems probable that the presence in the bacterial surface
of one of these two major OMPs is a requirement at least
for in vitro survival. This assertion is in contradiction with
the availability of 1omp25 mutants in B. abortus (Edmonds
et al., 2002; Manterola et al., 2007), a Brucella species naturally
lacking Omp31 due to a 25-kb deletion involving its encoding
gene (Vizcaíno et al., 2001a). Nevertheless, unlike B. ovis where
omp31b is a pseudogene (Vizcaíno et al., 2004), B. abortus
strains synthetize Omp31b (Martín-Martín et al., 2009), an
OMP sharing 67% of amino acid identity with Omp31 (Salhi
et al., 2003) and that could compensate for the absence of
Omp31 in this species. Research aiming to construct the
1omp251omp31b double mutant in the B. abortus genetic
background would help to a better understanding of the
relationships between the members of the Omp25/Omp31
family.
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According to the availability of the1omp101omp311omp25c
and 1omp311omp101omp25c mutants (with the same deleted
genes in a different order), B. ovis PA survives to the simultaneous
absence of Omp10 lipoprotein and major Omp31 and Omp25c,
together with the natural lack of Omp31b and Omp25b
(Martín-Martín et al., 2009). However, both mutants suffered
important phenotypic changes, such as strong in vitro growth
defects, quick autoagglutination, remarkable susceptibility to
polymyxin B, increased killing by murine macrophages in
the first 20 h of infection, defective internalization in HeLa
cells, and limited spleen colonization in mice inoculated with
106 CFU. Nevertheless, not only both strains replicate in murine
macrophages after 20 h of infection (Figure 6B and data
not shown) but at least B. ovis 1omp101omp311omp25c can
establish a chronic infection in mice, with important levels
of spleen colonization, when inoculated at 108 CFU/mouse
(Figure 2D).
Another finding regarding the Omp25/Omp31 family, and
that was further confirmed by confocal microscopy (data
not shown), is that all omp25c mutants are impaired for
internalization in HeLa cells (Figures 6D–F), while all strains
bearing the 1omp31 mutation (except the triple mutants also
bearing the omp25c deletion) internalize more efficiently than
the parental strain (Figures 6D–F and data not shown). Since
immunoblot assays showed that 1omp31 mutants had higher
levels of Omp25c, we postulated that Omp25c is involved in the
internalization of B. ovis PA in HeLa cells. This hypothesis is
supported by the immunoblots and HeLa cells assays performed
with omp31 and omp25c mutant and complemented strains
(Figure 7). Whether this characteristic is specific for HeLa
cells, for human cells or for non-professional phagocytes
independently of the animal species remains to be studied.
As expected (Martín-Martín et al., 2012) the 1cgs mutant did
not suffer drastic changes in the in vitro characteristics, but was
the only single mutant that was attenuated in the murine model
when it was inoculated at 106 CFU/mouse (Table 1). However,
a 100-fold increase of the inoculation dose led to high splenic
infection levels at both the acute and chronic phase of infection
(Table 1) and to a kinetics of spleen colonization resembling
that observed in mice experimentally infected with 106 CFU of
the parental strain (data not shown; see the equivalent spleen
colonization profile of the 1omp311cgs mutant in Figure 2).
According to the similarities between the parental strain and
the 1cgs mutant regarding their behavior in the cellular models
of professional and non-professional phagocytes used in this
work (Figures 6C,F) the attenuation of the 1cgs mutant of
B. ovis PA does not seem to be due to killing inside phagocytic
cells. However, since we have used individual cell lines, a
defective interaction with one or more types of professional
and/or non-professional phagocytes of BALB/c mice cannot be
discarded. In fact, 1cgs mutants of B. abortus 2308 and S19
are defective in both HeLa cells (Briones et al., 2001; Arellano-
Reynoso et al., 2005; Roset et al., 2006, 2014) and peritoneal
macrophages of C57BL/6 mice (Arellano-Reynoso et al., 2005)
but, on the contrary, they behave as the parental strains in bone
marrow cells also obtained from C57BL/6 mice (Salcedo et al.,
2008; Roset et al., 2014). Another possible explanation for the
attenuation of B. ovis 1cgs could be related to the association
that has been established between CβGs and a dual pro- and
anti-inflammatory response that transiently recruits neutrophils
and suggests a controlled local inflammatory response (Degos
et al., 2015). This controlled inflammatory response might be
important for the establishment of the Brucella infection, since
survival and replication inside phagocytes is a characteristic trait
of Brucella that provides the bacterium with a safe environment.
A strong inflammatory process would trigger a detrimental
immune response against the pathogen but, on the contrary, a
diminished inflammatory response in the absence of CβGs would
reduce the presence of suitable target cells for Brucella replication
and, therefore, could influence the outcome of infection.
The 1omp311cgs double mutant, defective in a major OMP
and in periplasmic CβGs, maintained or exacerbated the most
severe phenotype of the corresponding single mutants. Thus,
the susceptibility to DOC (Table 4) and in vitro growth defects
were more prominent in the 1omp311cgs mutant than in the
single mutants, which would be in accordance with cell envelope
modifications compromising the permeability of the bacterial
cell to nutrients and toxic compounds. Strikingly, despite its
important in vitro growth impairment and its increased killing
during the first stage of infection in murine macrophages
(Figure 6C), the 1omp311cgs mutant behaved similarly to the
1cgs mutant in the mouse model, except for a lower spleen
colonization at W3 p.i. (Table 1, Figure 2, and data not shown).
Additionally, a third deletion of omp10 or omp19 did not produce
apparent differences with respect to the 1omp311cgs mutant in
any of the characteristics evaluated and attenuation of the 1cgs
mutant was not drastically intensified by the deletion of omp10,
omp19, bepC, ugpB, or omp25 (Table 1).
Similarly to B. ovis 1omp311cgs, the 1omp101omp31
1omp25c mutant suffered a higher decrease of the intracellular
CFU during the first 20 h of macrophage infection but both
mutants multiplied properly after that moment (Figures 6B,C).
This ability to replicate intracellularly might explain why, despite
their impairment to infect mice at doses of 106 CFU/mouse,
they persisted at least until week 11 p.i. – with splenic counts
equivalent to those of the parental strain at that moment –
when 108 CFU were inoculated (Figure 2). Increased killing
inside professional phagocytes at the onset of infection could
have dramatic effects on the outcome of infection when the
lower dose of infection is used. However, higher doses of
infection would allow some bacteria to escape to the bactericidal
mechanisms of phagocytes and reach the replicative niche to
establish a persistent infection thereafter. At least in part, the
higher reduction of intracellular CFU at t20 could be related
to a defective growth inside the phagocytes – mimicking that
observed in vitro for both mutants (Figure 1) – and that might
be due to alterations in OM permeability to nutrients and/or
toxic compounds. On the other side, both mutants showed
an opposed internalization pattern in HeLa non-professional
phagocytes (Figures 6E,F) that does not correlate with their
similar attenuation in mice. Since, in addition, other single
and multiple mutants with analogous profiles in HeLa cells
were not attenuated in mice (e.g., B. ovis 1omp101omp31 and
1omp251omp25c) (Table 1 and Figure 6), an altered behavior in
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HeLa cells of a B. ovis mutant does not imply attenuation in the
mouse model.
The1omp101ugpB1omp31 mutant behaved in macrophages
similarly to the 1omp311cgs and 1omp101omp311omp25c
mutants (Figure 6B). However, although during the first 3 W p.i.
the three mutants showed a similar pattern of spleen colonization
in mice (Figure 2), the 1omp101ugpB1omp31 mutant was
progressively cleared from spleen thereafter (Figure 2D).
Therefore, additional defects, preventing the establishment of a
chronic infection, must be present in the1omp101ugpB1omp31
mutant. It must be noted that after W5 p.i., concomitantly with
the splenic dampening of CFU, the antibody response induced
by B. ovis PA 1omp101ugpB1omp31 was higher than that
observed in mice infected with the parental strain (Figure 2F)
(P < 0.05), despite the higher spleen colonization of the latter
(Figure 2A). This increased humoral immunity might contribute
to the clearance of the mutant but, at the same time, be a
relevant characteristic for an attenuated vaccine. Clearing of
the mutant after W3 p.i. could also be related with defects
impairing its colonization and/or survival inside reservoir cells
involved in sustaining the chronic phase of infection. In the
case of B. abortus, alternatively activated macrophages – more
abundant during the chronic phase of infection – have been
described as preferential target cells for survival and replication
in mice (Xavier et al., 2013). This preference has been related
with an increase in glucose availability in these cells (Xavier
et al., 2013), which adds new evidence about the relevant role of
metabolism in the acute phase of infection and/or in sustaining
persistent Brucella infection (Hong et al., 2000; Ronneau et al.,
2016; Barbier et al., 2018). Since transport through membranes
of metabolic substrates, metals, and other compounds is a
key mechanism for bacterial homeostasis, the changes in the
bacterial surface suffered by the 1omp101ugpB1omp31 mutant
might lead to an altered transport of essential molecules that
could impair survival in the reservoir cells. However, these
changes would not have dramatic effects under in vitro growth
conditions, at least in the culture medium used in this work
(Figure 1).
According to its attenuation profile, the 1omp101ugpB
1omp31 mutant was considered the best candidate to evaluate
its vaccine properties against in the mouse model. Three weeks
after the challenge, when B. ovis PA reaches its peak of infection
in unvaccinated mice (Figure 2), neither the virulent strain
nor the vaccine strain were detected in spleen, while both
strains were detected – although in low levels – in some mice
vaccinated with B. melitensis Rev1 (Figure 8F). The protective
activity of B. ovis 1omp101ugpB1omp31 was accompanied by
a good antibody response against B. ovis PA whole cells that
was significantly higher than that obtained with B. melitensis
Rev1 by the time of challenge (Figure 8F) and even higher
(P < 0.05) than that observed in mice infected with the parental
strain (Figure 2F). The development of specific antibodies is
critical for the protective activity against B. melitensis of both
killed and live strains (Vitry et al., 2014) and was described as
even more relevant than cell-mediated immunity in protecting
against B. ovis infection (Jiménez de Bagüés et al., 1994).
Accordingly, the strong humoral immune response elicited by
B. ovis1omp101ugpB1omp31 could account for its remarkable
protective activity against B. ovis. The similar levels of specific
IgG1, IgG2a, and IgG2b suggest a mixed Th1/Th2 response, also
observed with other B. ovis PA attenuated mutants (Sancho et al.,
2014), that is considered as an advantage for attenuated live
vaccines in controlling both early and late events in Brucella
infections (Vitry et al., 2014). B. ovis1omp101ugpB1omp31 also
induced a memory immune response evidenced by the profile of
cytokine secretion obtained with splenocytes of vaccinated mice
after re-stimulation with B. ovis PA whole cells (Figure 8). The
cytokine response, at least regarding the parameters evaluated
in this work, resembled that obtained with the classical vaccine
B. melitensis Rev1, the best available vaccine against B. ovis
with proved protective activity in the natural host (OIE, 2017b).
Both vaccination groups showed remarkable levels of IFN-g,
key cytokine for the control of Brucella infections (Zhan and
Cheers, 1993; Murphy et al., 2001; Figure 8). Important secretion
of IL-10, described as an anti-inflammatory cytokine that also
suppresses phagolysosome fusion in macrophages contributing
to Brucella survival in the host (Corsetti et al., 2013; Hop et al.,
2018), was also detected in both vaccination groups (Figure 8).
However, since both vaccines provided good protection against
infection, this increase in IL-10 levels could reflect a strong
activation of the immune response after a second exposure,
that would neutralize the pathogen but that could also have
detrimental effects for the host and would need to be controlled.
Although mutants should be evaluated simultaneously
to establish accurate comparisons, and other experimental
conditions in the murine model would provide a more
accurate information (e.g., different challenge doses, interval
vaccination-challenge), the level of protection conferred by the
1omp101ugpB1omp31 mutant against B. ovis infection seems
better than that previously described for other B. ovis attenuated
vaccines inoculated by the i.p. route (Sancho et al., 2014; Soler-
Lloréns et al., 2014; Silva et al., 2015b). Additionally, a 1abcAB
mutant of B. ovis, which is defective in a species-specific ABC
transporter (Silva et al., 2011) and that even encapsulated
did not provide good protection level in mice (Silva et al.,
2015b), protected against B. ovis in rams (Silva et al., 2015a).
Accordingly, the results obtained in this work encourage the
evaluation of B. ovis 1omp101ugpB1omp31 as vaccine in the
natural host. Moreover, the usefulness of B. ovis 1omp311cgs
and 1omp101omp311omp25c in rams should not be discarded,
since the mouse model – although considered a good approach to
evaluate the virulence of Brucella strains – has limitations (Kahl-
McDonagh and Ficht, 2006; Grilló et al., 2012) and some virulent
mutants in the mouse model were found attenuated in the natural
host (Bellaire et al., 2003). Additionally, considering that they
are avirulent in mice at low doses of infection, that they do not
reach the maximum levels of infection at higher infection doses
(Figure 2) and that they barely induce inflammation in spleen
(Figure 2), the 1omp311cgs and 1omp101omp311omp25c
mutants might be unable to produce epididymitis in rams.
In addition to the protective properties, the three attenuated
mutants would provide diagnostic advantages. They would not
interfere with the serological diagnosis of infections caused by
smooth Brucella and, since they are defective in major Omp31
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that has been proposed as an interesting diagnostic antigen for
B. ovis infection (Vizcaíno et al., 2001b), they would favor the
differentiation between vaccinated and infected animals by using
Omp31 as diagnostic antigen.
In addition to the development of a vaccine candidate against
B. ovis, the results obtained in this work provide new information
about the relationships among cell-envelope molecules of B. ovis
and the peculiar characteristics of its OM. This knowledge
could help to explain why B. ovis, despite its reported genome
degradation (Tsolis et al., 2009), establishes persistent infections
in its natural host whereas rough mutants derived from S Brucella
do not or why its pathogenicity differs from that of B. melitensis
in the same preferred host.
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